WallStreetZenWallStreetZen

NASDAQ: ATHA
Athira Pharma Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$0.31-0.03 (-8.82%)
Updated Mar 26, 2025
ATHA Price
$0.31
Fair Value Price
N/A
Market Cap
$12.26M
52 Week Low
$0.30
52 Week High
$3.67
P/E
-0.12x
P/B
0.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$97M
Beta
1.37
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ATHA Overview

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and stop neurodegeneration brought on by Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease.Known as M3 Biotechnology, Inc. until 2019/04, the company was incorporated in 2011 and is headquartered in Bothell, WA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ATHA's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ATHA
RankedUnranked of 479

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.48A
Aurinia Pharmaceuticals (AUPH)
$8.52A
Jazz Pharmaceuticals (JAZZ)
$130.88A
View Top Biotech Stocks

Be the first to know about important ATHA news, forecast changes, insider trades & much more!

ATHA News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATHA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATHA is good value based on its book value relative to its share price (0.27x), compared to the US Biotechnology industry average (4.53x)
P/B vs Industry Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATHA due diligence checks available for Premium users.

Valuation

ATHA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.12x
Industry
-115.59x
Market
31.65x

ATHA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.27x
Industry
4.53x
ATHA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATHA's financial health

Profit margin

Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
ATHA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$58.8M
Liabilities
$13.9M
Debt to equity
0.31
ATHA's short-term assets ($54.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHA's short-term assets ($54.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.0M
Investing
-$2.8M
Financing
$34.0k
ATHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATHA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ATHA–$12.26M-6.27%-0.12x0.27x
APRE–$12.30M+2.28%-0.95x0.64x
KAPAF$12.33M-2.04%-3.84x3.70x
BRTXC$12.18M-8.33%-3.03x1.22x
ERNA–$12.02M-6.12%-0.07x7.06x
View Top Biotech Stocks

Athira Pharma Stock FAQ

What is Athira Pharma's quote symbol?

(NASDAQ: ATHA) Athira Pharma trades on the NASDAQ under the ticker symbol ATHA. Athira Pharma stock quotes can also be displayed as NASDAQ: ATHA.

If you're new to stock investing, here's how to buy Athira Pharma stock.

What is the 52 week high and low for Athira Pharma (NASDAQ: ATHA)?

(NASDAQ: ATHA) Athira Pharma's 52-week high was $3.67, and its 52-week low was $0.30. It is currently -91.44% from its 52-week high and 4.32% from its 52-week low.

How much is Athira Pharma stock worth today?

(NASDAQ: ATHA) Athira Pharma currently has 39,042,445 outstanding shares. With Athira Pharma stock trading at $0.31 per share, the total value of Athira Pharma stock (market capitalization) is $12.26M.

Athira Pharma stock was originally listed at a price of $17.11 in Sep 18, 2020. If you had invested in Athira Pharma stock at $17.11, your return over the last 4 years would have been -98.16%, for an annualized return of -63.19% (not including any dividends or dividend reinvestments).

How much is Athira Pharma's stock price per share?

(NASDAQ: ATHA) Athira Pharma stock price per share is $0.31 today (as of Mar 26, 2025).

What is Athira Pharma's Market Cap?

(NASDAQ: ATHA) Athira Pharma's market cap is $12.26M, as of Mar 27, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Athira Pharma's market cap is calculated by multiplying ATHA's current stock price of $0.31 by ATHA's total outstanding shares of 39,042,445.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.